Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 101Glioblastoma 85Glioma 58Central Nervous System Neoplasms 34Astrocytoma 27Neuroblastoma 26Gliosarcoma 19Breast Neoplasms 19Neoplasms 18Oligodendroglioma 17Recurrence 14Neoplasm Metastasis 13Medulloblastoma 12Ependymoma 11Carcinoma, Non-Small-Cell Lung 11Lymphoma 9Sarcoma 8Osteosarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neuroma, Acoustic 7Meningioma 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lung Neoplasms 7Hodgkin Disease 7Burkitt Lymphoma 7Wilms Tumor 6Sezary Syndrome 6Neuroectodermal Tumors, Primitive 6Mycosis Fungoides 6

Interventions

Corticotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Brain Edema × CNS × Clear all
NCT00226668 2008-01-03

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Celtic Pharma Development Services

Phase 3 Withdrawn
120 enrolled
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡